Rebecca Rossetti1, Tara Smith2, Wei Luo3, Silvina Masciotra3. 1. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, United States. Electronic address: nvp4@cdc.gov. 2. Oak Ridge Institute for Science and Education, United States. 3. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, United States.
Abstract
BACKGROUND: The Reveal G4 antibody rapid test is FDA-approved for HIV-1 detection using the versions LAB S/P and POC in CLIA-moderate complexity settings with serum/plasma and whole blood, respectively. The same Reveal tests are CE-marked for HIV-1 and HIV-2 detection in laboratory and point-of-care (POC) settings. OBJECTIVE: We compared the performance of G4 LAB S/P with plasma and POC with whole blood (blood) for detecting early and established HIV-1/HIV-2 infections. STUDY DESIGN: Matched well-characterized plasma and simulated blood were used to evaluate: sensitivity in 104 HIV-1 and 55 HIV-2 established infections, specificity in 49 HIV-negative, and reactivity in early HIV-1 infection in a performance panel (n=38) and 18 plasma panels from seroconverters (SCs, n=183). Median number of days after first RNA-positive was calculated for 13 SCs. Impact of viral suppression (VS) was evaluated in 3 SCs receiving early antiretroviral therapy (ART). RESULTS: Sensitivity was 100 % for HIV-1 and 98.18 % for HIV-2, while specificity was 100 %. All 38 plasma and blood become reactive by Fiebig stage V. Of 18 SCs, 10 had similar reactivity in plasma/blood, 7 showed delayed reactivity in blood, and 1 was nonreactive in plasma/blood. The median days for a G4-reactive after first RNApositive was 13 for plasma and 14 for blood. Long-term VS had no impact on G4 reactivity. CONCLUSIONS: Overall reactivity in early HIV-1 infections is delayed by one day in blood compared to plasma. If FDA-approved for POC settings, the G4 POC is a fast sensitive screening tool for HIV-1/HIV-2-specific IgG even during VS. Published by Elsevier B.V.
BACKGROUND: The Reveal G4 antibody rapid test is FDA-approved for HIV-1 detection using the versions LAB S/P and POC in CLIA-moderate complexity settings with serum/plasma and whole blood, respectively. The same Reveal tests are CE-marked for HIV-1 and HIV-2 detection in laboratory and point-of-care (POC) settings. OBJECTIVE: We compared the performance of G4 LAB S/P with plasma and POC with whole blood (blood) for detecting early and established HIV-1/HIV-2 infections. STUDY DESIGN: Matched well-characterized plasma and simulated blood were used to evaluate: sensitivity in 104 HIV-1 and 55 HIV-2 established infections, specificity in 49 HIV-negative, and reactivity in early HIV-1 infection in a performance panel (n=38) and 18 plasma panels from seroconverters (SCs, n=183). Median number of days after first RNA-positive was calculated for 13 SCs. Impact of viral suppression (VS) was evaluated in 3 SCs receiving early antiretroviral therapy (ART). RESULTS: Sensitivity was 100 % for HIV-1 and 98.18 % for HIV-2, while specificity was 100 %. All 38 plasma and blood become reactive by Fiebig stage V. Of 18 SCs, 10 had similar reactivity in plasma/blood, 7 showed delayed reactivity in blood, and 1 was nonreactive in plasma/blood. The median days for a G4-reactive after first RNApositive was 13 for plasma and 14 for blood. Long-term VS had no impact on G4 reactivity. CONCLUSIONS: Overall reactivity in early HIV-1 infections is delayed by one day in blood compared to plasma. If FDA-approved for POC settings, the G4 POC is a fast sensitive screening tool for HIV-1/HIV-2-specific IgG even during VS. Published by Elsevier B.V.
Entities:
Keywords:
HIV diagnostics; HIV-1; HIV-2; Rapid test
Authors: Kevin P Delaney; Bernard M Branson; Apurva Uniyal; Susan Phillips; Debra Candal; S Michele Owen; Peter R Kerndt Journal: Clin Infect Dis Date: 2011-01-15 Impact factor: 9.079
Authors: Nan Jiang; Rajib Ahmed; Mylon Damayantharan; Barış Ünal; Haider Butt; Ali K Yetisen Journal: Adv Healthc Mater Date: 2019-05-13 Impact factor: 9.933
Authors: Kevin P Delaney; Debra L Hanson; Silvina Masciotra; Steven F Ethridge; Laura Wesolowski; Sherry Michele Owen Journal: Clin Infect Dis Date: 2016-10-12 Impact factor: 9.079
Authors: Silvina Masciotra; J Steven McDougal; Jane Feldman; Patrick Sprinkle; Laura Wesolowski; S Michele Owen Journal: J Clin Virol Date: 2011-10-05 Impact factor: 3.168
Authors: Jonathan T Lipscomb; William M Switzer; Jin-fen Li; Silvina Masciotra; S Michele Owen; Jeffrey A Johnson Journal: J Infect Dis Date: 2014-06-12 Impact factor: 5.226
Authors: Christian Arbelaez; Brian Block; Elena Losina; Elizabeth A Wright; William M Reichmann; Regina Mikulinsky; Jessica D Solomon; Matthew M Dooley; Rochelle P Walensky Journal: Int J Emerg Med Date: 2009-09-01
Authors: Silvina Masciotra; Wei Luo; Ae S Youngpairoj; M Susan Kennedy; Susan Wells; Krystin Ambrose; Patrick Sprinkle; S Michele Owen Journal: J Clin Virol Date: 2013-08-02 Impact factor: 3.168
Authors: S M Owen; C Yang; T Spira; C Y Ou; C P Pau; B S Parekh; D Candal; D Kuehl; M S Kennedy; D Rudolph; W Luo; N Delatorre; S Masciotra; M L Kalish; F Cowart; T Barnett; R Lal; J S McDougal Journal: J Clin Microbiol Date: 2008-03-05 Impact factor: 5.948
Authors: Patrick Ndase; Connie Celum; Lara Kidoguchi; Allan Ronald; Kenneth H Fife; Elizabeth Bukusi; Deborah Donnell; Jared M Baeten Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240